Day: March 26, 2025

TRANSFER OF HARVIA’S OWN SHARES AS REWARDS UNDER THE INCENTIVE PROGRAM

Written by Customer Service on March 26, 2025. Posted in Public Companies.

HARVIA PLC STOCK EXCHANGE RELEASE March 26, 2025 AT 2.15 P.M. EET The Board of Directors of Harvia Plc has on 25 February 2025 decided on a directed share issue without consideration for the payment of rewards earned under the company’s share-based incentive program. The share payments concern the performance period 2022–2024 of the company’s share-based incentive program launched in 2022. In the share issue, 9,852 own shares held by the company have today been transferred without consideration to the key employees participating in the share-based incentive program in accordance with the terms and conditions of the program. The company holds a total of 5,355 own shares after the transfer of shares under the incentive program. The decision on the transfer of shares is...

SAIC Announces ReadyOne™ Foundational: Latest Digital Engineering Ecosystem for Accelerated Innovation and Mission Effectiveness

Written by Customer Service on March 26, 2025. Posted in Public Companies.

RESTON, Va., March 26, 2025 (GLOBE NEWSWIRE) — Science Applications International Corp. (NASDAQ: SAIC) has announced the launch of ReadyOne™ Foundational – the company’s commercial-grade solution for a rapidly deployable, cloud-based digital engineering ecosystem that meets the Department of Defense (DoD) Instruction 5000.97 mandate and unique mission requirements of government customers. It is now available on the AWS Marketplace to accelerate deployment and help government avoid developing capabilities that are already commercially available. ReadyOne™ Foundational’s built-in digital thread accelerator unifies disparate data, tools and teams in real-time through a configurable, turnkey solution – enabling an out-of-the-box adoption of best practices in digital engineering. This offering grants customers access...

VERSES® Announces Consolidation of Class A Subordinate Voting Shares in Preparation for a Planned Uplisting to NASDAQ

Written by Customer Service on March 26, 2025. Posted in Public Companies.

VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE:VERS) (OTCQB:VRSSF) (“VERSES” or the “Company”) a cognitive computing company specializing in next-generation intelligent software systems, is pleased to announce the consolidation of its Class A Subordinated Voting Shares in connection with an application to uplist such shares on the Nasdaq Capital Market (“Nasdaq”). As part of the planned uplisting, the Company is consolidating all issued and outstanding Class A Subordinate Voting Shares (“Subordinated Voting Shares”) on the basis of one (1) post-consolidated Subordinated Voting Share for every nine (9) pre-consolidated Subordinated Voting Share held (the “Consolidation”). “The consolidation is one of many initiatives that the Company is implementing in preparation for our intended...

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Written by Customer Service on March 26, 2025. Posted in Earnings Releases And Operating Results.

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) Cash of $69.8 million as of December 31, 2024, expected to fund operations into 2027 LONDON, March 26, 2025 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2024, and provided recent corporate highlights. “2024 was a year of focused execution and strategic advancement at Mereo, driving our lead programs closer to key milestones,” said Dr. Denise Scots-Knight, Chief Executive Officer...

BIO-key Completes Initial Biometric-Based Identity and Access Management Deployment for New International Defense Agency Customer in Record Time

Written by Customer Service on March 26, 2025. Posted in Public Companies.

Solution Features PortalGuard On-Prem, WEB-key Biometric Software, FIPS Certified Fingerprint Scanners, and Passkey:YOU FIDO2 Passkeys MADRID, Spain and HOLMDEL, N.J., March 26, 2025 (GLOBE NEWSWIRE) — BIO-key® International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication solutions has successfully completed the deployment of a comprehensive suite of BIO-key biometric-based IAM solutions for a new International Defense Agency customer. The full deployment for the initial sites was completed in just four days, showcasing the efficiency, seamless integration, and collaboration between BIO-key and the customer’s IT team. The deployment incorporates these BIO-key solutions:PortalGuard On-Prem – A highly secure IAM platform providing Multi-factor Authentication (MFA) and Single...

Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting

Written by Customer Service on March 26, 2025. Posted in Public Companies.

Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual Meeting Pre-clinical data on Medicenna’s first-in-class Masked and Tumor Targeted Bifunctional anti-PD1-IL2 Superkine, MDNA113, will also be presented TORONTO and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that two posters will be presented at the American Association for Cancer Research Annual Meeting 2025 (AACR 2025) taking place April 25-30, 2025 in Chicago, Illinois. The Company will present an update from its Phase 1/2 ABILITY-1 Study evaluating MDNA11, the only long-acting, ‘beta-enhanced not-alpha’ interleukin-2 (IL-2) super-agonist...

Trident Announces Strategic Collaboration with Two Global E-Commerce Firms

Written by Customer Service on March 26, 2025. Posted in Public Companies.

Trident’s strategic collaboration with e-commerce players Silkoo and Haitu will combine their unique strengths to drive innovation and mutual growth SINGAPORE, March 26, 2025 (GLOBE NEWSWIRE) — Trident Digital Tech Holdings Ltd (“Trident” or the “Company,” NASDAQ: TDTH), a leading catalyst for digital transformation in technology optimization services and Web 3.0 activation based in Singapore, today announced it has entered into a strategic collaboration agreement (the “Collaboration Agreement”) with two partners in the e-commerce sector. Per the Collaboration Agreement, Trident will join forces with Silkoo Dutyfree Limited (“Silkoo”), an e-commerce retailer and import-export trader, and Haitu Trade Co., Limited (“Haitu”), an e-commerce entity specializing in beauty and cosmetics, to foster a synergistic partnership that drives...

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

Written by Customer Service on March 26, 2025. Posted in Earnings Releases And Operating Results.

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and late 2025 on track for MET-233i, an ultra-long acting amylin analog currently in Phase 1 Oral formulation optimization study on track to support initiation of clinical trials for MET-224o and MET097o, with MET-224o data expected in late 2025 Completed IPO with gross proceeds of approximately $316.2 million, extending runway into 2027 NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today reported fourth quarter and full year 2024 financial results and provided an update on pipeline progress. “2024...

PyroGenesis Schedules 2024 Fiscal Year Financial Results and Business Update Conference Call

Written by Customer Service on March 26, 2025. Posted in Earnings Releases And Operating Results.

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company that designs, develops, manufactures and commercializes advanced all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, today announces that it will host a conference call at 10:00 AM Eastern Time on Tuesday, April 1st, 2025 to discuss the Company’s financial results for the fiscal year 2024 which ended December, 31, 2024, as well as provide an update to the Company’s progress and other developments. To access the conference call by telephone, please pre-register using the following link: https://register-conf.media-server.com/register/BI4309c0c8634741c9bf5b19154e79ce09....

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Written by Customer Service on March 26, 2025. Posted in Earnings Releases And Operating Results.

Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription growth from third quarter 2024 to fourth quarter 2024 YARDLEY, Pa., March 26, 2025 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2024, and provided recent operational highlights. Fourth Quarter 2024 and Recent Highlights New Prescriptions (NRx) and Total Prescriptions (TRx)An inflection in prescription demand first observed in September 2024 NRx continued in fourth quarter 2024 and extended to TRx. NRx increased 12% from approximately 25,600 in third quarter...

Day: March 26, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals